Business Description
Cynata Therapeutics Ltd
NAICS : 325620
ISIN : AU000000CYP7
Description
Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus. There are currently three active clinical trials taking place using Cymerus technology which are attempting to treat osteoarthritis, respiratory distress, and diabetic foot ulcers.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.86 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -0.5 | |||||
| 3-Year EPS without NRI Growth Rate | 2.9 | |||||
| 3-Year FCF Growth Rate | -11.2 | |||||
| 3-Year Book Growth Rate | -41.3 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 62.66 | |||||
| 9-Day RSI | 54.84 | |||||
| 14-Day RSI | 51 | |||||
| 6-1 Month Momentum % | -20.37 | |||||
| 12-1 Month Momentum % | 79.17 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.58 | |||||
| Quick Ratio | 5.58 | |||||
| Cash Ratio | 5.3 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.8 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -80.72 | |||||
| ROA % | -71.59 | |||||
| ROIC % | -572.88 | |||||
| ROC (Joel Greenblatt) % | -3475.35 | |||||
| ROCE % | -103.91 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 5.38 | |||||
| Price-to-Tangible-Book | 7 | |||||
| EV-to-EBIT | -3.28 | |||||
| EV-to-EBITDA | -3.35 | |||||
| EV-to-FCF | -4.24 | |||||
| Price-to-Net-Current-Asset-Value | 7 | |||||
| Price-to-Net-Cash | 7 | |||||
| Earnings Yield (Greenblatt) % | -30.48 | |||||
| FCF Yield % | -21.06 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cynata Therapeutics Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | |||
| EPS (TTM) (A$) | -0.054 | ||
| Beta | 0.9 | ||
| Volatility % | 76.31 | ||
| 14-Day RSI | 51 | ||
| 14-Day ATR (A$) | 0.01173 | ||
| 20-Day SMA (A$) | 0.206 | ||
| 12-1 Month Momentum % | 79.17 | ||
| 52-Week Range (A$) | 0.12 - 0.345 | ||
| Shares Outstanding (Mil) | 225.25 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cynata Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cynata Therapeutics Ltd Stock Events
| Event | Date | Price(A$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Cynata Therapeutics Ltd Frequently Asked Questions
What is Cynata Therapeutics Ltd(ASX:CYP)'s stock price today?
The current price of ASX:CYP is A$0.21. The 52 week high of ASX:CYP is A$0.35 and 52 week low is A$0.12.
When is next earnings date of Cynata Therapeutics Ltd(ASX:CYP)?
The next earnings date of Cynata Therapeutics Ltd(ASX:CYP) is 2025-02-21 Est..
Does Cynata Therapeutics Ltd(ASX:CYP) pay dividends? If so, how much?
Cynata Therapeutics Ltd(ASX:CYP) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers